These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 11872291)
1. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Lee LN; Stock RG; Stone NN Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):444-52. PubMed ID: 11872291 [TBL] [Abstract][Full Text] [Related]
2. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA; Stock RG; Stone N Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768 [TBL] [Abstract][Full Text] [Related]
3. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266 [TBL] [Abstract][Full Text] [Related]
4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788 [TBL] [Abstract][Full Text] [Related]
5. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. Anderson PR; Hanlon AL; Movsas B; Hanks GE Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540 [TBL] [Abstract][Full Text] [Related]
7. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244 [TBL] [Abstract][Full Text] [Related]
8. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Ko EC; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944 [TBL] [Abstract][Full Text] [Related]
9. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure. Stock RG; Berkowitz J; Blacksburg SR; Stone NN BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680 [TBL] [Abstract][Full Text] [Related]
10. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Stock RG; Stone NN Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181 [TBL] [Abstract][Full Text] [Related]
11. Combined modality treatment in the management of high-risk prostate cancer. Stock RG; Cahlon O; Cesaretti JA; Kollmeier MA; Stone NN Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1352-9. PubMed ID: 15275720 [TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111 [TBL] [Abstract][Full Text] [Related]
13. Predictors of metastatic disease after prostate brachytherapy. Forsythe K; Burri R; Stone N; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025 [TBL] [Abstract][Full Text] [Related]
14. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535 [TBL] [Abstract][Full Text] [Related]
15. Isotope selection for patients undergoing prostate brachytherapy. Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561 [TBL] [Abstract][Full Text] [Related]
16. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
17. High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis. Oh RJ; Yoshioka Y; Tanaka E; Shiomi H; Sumida I; Isohashi F; Suzuki O; Konishi K; Kawaguchi Y; Nakamura S; Kato M; Inoue T Radiat Med; 2006 Jan; 24(1):58-64. PubMed ID: 16715663 [TBL] [Abstract][Full Text] [Related]
18. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Stokes SH Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314 [TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy. Sherertz T; Wallner K; Merrick G; Cavanagh W; Butler W; Reed D; True L Cancer J; 2004; 10(5):301-6. PubMed ID: 15530259 [TBL] [Abstract][Full Text] [Related]
20. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]